 use probenecid chemoprotector cisplatin nephrotoxicity Probenecid cisplatin CP secretion humans protects CP-induced nephrotoxicity rats authors Phase trial doses CP probenecid chemoprotector Fifty-four courses CP doses infusion patients renal impairment dose Ototoxicity dose-limiting toxicity patients decibel dB loss Seven percent courses leukocyte count platelet count /microliters patients developed neurotoxicity Correlating pharmacokinetic data toxicity authors high cumulative dose area curve AUC unbound platinum cumulative AUC ototoxicity peripheral neuropathy probenecid CP nephrotoxicity warrants investigation unique mechanism action lack toxicity chemoprotectors